UBS Raises price Target on Foundation Medicine (FMI) to $22
- Top 10 News for 10/17 - 10/21: Merger Rumors Abound; CEOs Depart; Tesla Kicks Autopilot Up A Notch
- Wall Street ends little changed; Microsoft hits record
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
UBS reiterated a Neutral rating on Foundation Medicine (NASDAQ: FMI), and raised the price target to $22.00 (from $16.00), following the company's announced expanded Local Coverage Determination.
Analyst Jonathan Groberg commented, "Palmetto, a Medicare contractor, announced last Thursday an expanded Local Coverage Determination (LCD) to include all stage IIIB/IV non-small cell lung cancer (NSCLC) patients. This new policy now provides coverage for comprehensive genomic profiling (CGP) for metastatic NSCLC patients who have not been tested for genomic mutations or who have tested negative for EGFR mutations. This is important for patients as CGP detected alterations may indicate eligibility for targeted treatment or immunotherapy."
Shares of Foundation Medicine closed at $23.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Imperial Capital Raises Price Target on Proofpoint (PFPT) Following Strong 3Q Results
- Jefferies Cuts Price Target on Boston Beer Co. (SAM) to $140 Following Weak 3Q
- FBR Capital Raises price Target on Gentex Corp (GNTX) to $22
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!